ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.88 USD
+0.25 (9.51%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $2.86 -0.02 (-0.69%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CDXC 2.88 +0.25(9.51%)
Will CDXC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CDXC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDXC
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
CDXC: What are Zacks experts saying now?
Zacks Private Portfolio Services
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
Other News for CDXC
Roth MKM Remains a Buy on Chromadex (CDXC)
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
ChromaDex Corporation 2024 Q2 - Results - Earnings Call Presentation
ChromaDex: Q2 Earnings Snapshot
ChromaDex Corporation Reports Second Quarter 2024 Financial Results